NERVOUS SYSTEM HEALTH

Alzheimer’s drug Leqembi: What to know

Alzheimer’s drug Leqembi received full approval from the U.S. Food and Drug Administration. An expert explains why this is a milestone in the treatment of the progressive disease.

FDA approves Amylyx ALS drug

Amylyx says doctors will be able to prescribe Relyvrio immediately. The drugmaker anticipates prescriptions will be filled and shipped from specialty pharmacies within the next four to six weeks.

Biogen shares slip as Alzheimer's drug faces new setback

Shares of Biogen slipped nearly 4% in pre-market trading Wednesday after the biotech company's new Alzheimer's drug Aduhelm (aducanumab) received a "negative trend vote" from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP).